Availability and prescribing of extended release buprenorphine injection for Medicaid beneficiaries, 2018-2022 - Ross, Rachael K.; Rudolph, Kara E.; Shover, Chelsea (medRxiv, 2024)
Background and aims Extended release buprenorphine injection (INJ-BUP) has been available in the United States since 2018. INJ-BUP has the potential to positively impact OUD treatment outcomes by providing additional treatment options and patient choice. We aimed to describe the availability and prescribing of INJ-BUP for Medicaid beneficiaries since its availability, nationwide and by state.Methods To assess availability, we measured the number of substance use disorder (SUD) facilities that offered INJ-BUP and accepted Medicaid insurance in 2018-2021 and calculated the percentage of all facilities offering medications of OUD. To assess prescribing, we measured the number of prescriptions for INJ-BUP paid by Medicaid 2018-2022 and calculated the percentage of all buprenorphine prescriptions paid by Medicaid. Data sources were publicly available.Results The number of facilities that offered INJ-BUP and accepted Medicaid insurance increased from 360 (2.5% of all SUD facilities offering medication) in 2018 to 2,257 (13.3%) in 2021. The number of prescriptions for INJ-BUP paid by Medicaid increased from 4,322 (0.1% of all buprenorphine prescriptions) in 2018 to 186,861 (2.0%) in 2022. There was notable variability in the number of facilities and prescriptions by state.Conclusions There has been exponential increase in the number of INJ-BUP prescriptions but uptake is much less than observed in other countries in shorter time periods. Limited availability at SUD treatment facilities that accept Medicaid may be one barrier to access.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants R01DA056407 and K01DA050771 from NIDA at NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the findings of this study are openly available at https://www.samhsa.gov/data/data-we-collect/n-ssats-national-survey-substance-abuse-treatment-services, https://data.medicaid.gov/datasets?theme%5B0%5D=State+Drug+Utilization, and https://portal.cms.gov/MSTR2021/servlet/mstrWeb?src=mstrWeb.2048001&ru=1&documentID=E8E899A911EB08AB795A0080EFE5D251. Code for this analysis is available at https://github.com/rachael-k-ross/Inj-BUP-Availability-Prescribing.https://www.samhsa.gov/data/data-we-collect/n-ssats-national-survey-substance-abuse-treatment-serviceshttps://data.medicaid.gov/datasets?theme%5B0%5D=State+Drug+Utilizationhttps://portal.cms.gov/MSTR2021/servlet/mstrWeb?src=mstrWeb.2048001&ru=1&documentID=E8E899A911EB08AB795A0080EFE5D251https://github.com/rachael-k-ross/Inj-BUP-Availability-Prescribing